Aurinia My 2024 Sell Call Was Wrong - So Im Upgrading To Hold In 2025 - Seeking Alpha
AUPH Stock | USD 7.95 0.05 0.62% |
Under 55% of Aurinia Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that many traders are impartial. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
Aurinia |
Aurinia My 2024 Sell Call Was Wrong - So Im Upgrading To Hold In 2025 Seeking Alpha
Read at news.google.com
Aurinia Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
45
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Aurinia Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Aurinia Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Aurinia Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aurinia Pharmaceuticals Historical Investor Sentiment
Investor biases related to Aurinia Pharmaceuticals' public news can be used to forecast risks associated with an investment in Aurinia. The trend in average sentiment can be used to explain how an investor holding Aurinia can time the market purely based on public headlines and social activities around Aurinia Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Aurinia Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Aurinia Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Aurinia Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals Maximum Pain Price Across April 17th 2025 Option Contracts
Aurinia Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Aurinia Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Aurinia Pharmaceuticals' options.
Aurinia Pharmaceuticals Fundamental Analysis
We analyze Aurinia Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aurinia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aurinia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Aurinia Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Aurinia Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aurinia Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aurinia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aurinia Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aurinia Pharmaceuticals Related Equities
BTAI | BioXcel Therapeutics | 1.88 | ||||
AKRO | Akero Therapeutics | 0.00 | ||||
MDGL | Madrigal Pharmaceuticals | 0.00 | ||||
EXEL | Exelixis | 0.36 | ||||
PTCT | PTC Therapeutics | 0.59 | ||||
SRPT | Sarepta Therapeutics | 0.64 | ||||
MCRB | Seres Therapeutics | 1.74 | ||||
AXSM | Axsome Therapeutics | 2.20 | ||||
VKTX | Viking Therapeutics | 2.79 | ||||
TERN | Terns Pharmaceuticals | 3.88 | ||||
TGTX | TG Therapeutics | 4.98 | ||||
HEPA | Hepion Pharmaceuticals | 5.26 |
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |